As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
17 Analysts have issued a Amylyx Pharmaceuticals forecast:
17 Analysts have issued a Amylyx Pharmaceuticals forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -157 -157 |
31%
31%
|
|
| EBIT (Operating Income) EBIT | -157 -157 |
30%
30%
|
|
| Net Profit | -149 -149 |
42%
42%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Josh Klee |
| Employees | 123 |
| Founded | 2013 |
| Website | www.amylyx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


